Beta Drugs Limited

NSEI:BETA Lagerbericht

Marktkapitalisierung: ₹20.6b

Beta Drugs Management

Management Kriterienprüfungen 4/4

Beta Drugs CEO ist Rahul Batra , ernannt in Jan 2021, hat eine Amtszeit von 3.83 Jahren. Die jährliche Gesamtvergütung beträgt ₹12.10M , bestehend aus 100% Gehalt und 0% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.41% der Aktien des Unternehmens, im Wert von ₹84.99M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.8 Jahre bzw. 7.3 Jahre.

Wichtige Informationen

Rahul Batra

Geschäftsführender

₹12.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts100.0%
Amtszeit als Geschäftsführer3.8yrs
Eigentum des Geschäftsführers0.4%
Durchschnittliche Amtszeit des Managements3.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder7.3yrs

Jüngste Management Updates

Recent updates

Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Rahul Batra im Vergleich zu den Einnahmen von Beta Drugs verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

₹410m

Jun 30 2024n/an/a

₹387m

Mar 31 2024₹12m₹12m

₹364m

Dec 31 2023n/an/a

₹356m

Sep 30 2023n/an/a

₹348m

Jun 30 2023n/an/a

₹327m

Mar 31 2023₹12mn/a

₹307m

Dec 31 2022n/an/a

₹298m

Sep 30 2022n/an/a

₹289m

Jun 30 2022n/an/a

₹269m

Mar 31 2022₹8m₹8m

₹248m

Dec 31 2021n/an/a

₹216m

Sep 30 2021n/an/a

₹183m

Jun 30 2021n/an/a

₹150m

Mar 31 2021₹6m₹6m

₹117m

Dec 31 2020n/an/a

₹106m

Sep 30 2020n/an/a

₹95m

Jun 30 2020n/an/a

₹94m

Mar 31 2020₹5m₹5m

₹94m

Sep 30 2019n/an/a

₹97m

Jun 30 2019n/an/a

₹89m

Mar 31 2019₹1m₹1m

₹80m

Vergütung im Vergleich zum Markt: RahulDie Gesamtvergütung ($USD143.26K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Indian ($USD187.40K).

Entschädigung vs. Einkommen: RahulDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Rahul Batra (41 yo)

3.8yrs

Amtszeit

₹12,100,000

Vergütung

Mr. Rahul Batra serves as the Chairman & Managing Director of Beta Drugs Limited since January 27, 2021. He had been Whole Time Director of Beta Drugs Limited since August 1, 2014 until January 27, 2021. H...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Rahul Batra
Chairman & MD3.8yrs₹12.10m0.41%
₹ 85.0m
Varun Batra
Joint MD & Whole Time Director3.8yrs₹12.10m0.35%
₹ 71.2m
Nipun Arora
Chief Financial Officer3.7yrs₹3.10mkeine Daten
Rajni Brar
Company Secretary & Compliance Officer7.3yrs₹911.55kkeine Daten
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director5.7yrs₹5.12mkeine Daten
Seema Chopra
Whole Time Directorno data₹1.19mkeine Daten
Sanjeev Chopra
Vice President of Technicalno datakeine Datenkeine Daten

3.8yrs

Durchschnittliche Betriebszugehörigkeit

40.5yo

Durchschnittliches Alter

Erfahrenes Management: BETADas Führungsteam des Unternehmens gilt als erfahren (3.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Rahul Batra
Chairman & MD10.3yrs₹12.10m0.41%
₹ 85.0m
Varun Batra
Joint MD & Whole Time Director10.3yrs₹12.10m0.35%
₹ 71.2m
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director2.8yrs₹5.12mkeine Daten
Seema Chopra
Whole Time Director5.3yrs₹1.19mkeine Daten
Manmohan Khanna
Independent Director7.3yrskeine Datenkeine Daten
Rohit Parti
Independent Director7.3yrskeine Datenkeine Daten

7.3yrs

Durchschnittliche Betriebszugehörigkeit

48yo

Durchschnittliches Alter

Erfahrener Vorstand: BETADie Vorstandsmitglieder gelten als erfahren (7.3 Jahre durchschnittliche Amtszeit).